Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Haemonetics Corporation (NYSE:HAE) have been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $78.3333.

HAE has been the subject of several recent research reports. JPMorgan Chase & Co. cut their price objective on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Robert W. Baird set a $67.00 price objective on Haemonetics in a report on Friday, May 8th. BTIG Research reiterated a “buy” rating and set a $84.00 price objective on shares of Haemonetics in a report on Friday, June 26th. Finally, Mizuho increased their price objective on Haemonetics from $70.00 to $85.00 and gave the stock an “outperform” rating in a report on Monday, June 15th.

Institutional Trading of Haemonetics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Central Pacific Bank Trust Division raised its holdings in Haemonetics by 2.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 8,900 shares of the medical instruments supplier’s stock valued at $713,000 after buying an additional 188 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Haemonetics by 12.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,920 shares of the medical instruments supplier’s stock valued at $108,000 after buying an additional 211 shares in the last quarter. Quantinno Capital Management LP raised its holdings in Haemonetics by 9.0% during the second quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock valued at $261,000 after buying an additional 289 shares in the last quarter. UMB Bank n.a. raised its holdings in Haemonetics by 110.9% during the fourth quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 306 shares in the last quarter. Finally, Cardinal Capital Management raised its holdings in Haemonetics by 1.5% during the fourth quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock valued at $1,799,000 after buying an additional 321 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Price Performance

HAE opened at $75.20 on Wednesday. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics has a 12-month low of $47.31 and a 12-month high of $87.32. The stock has a fifty day moving average of $65.98 and a 200-day moving average of $66.62. The firm has a market capitalization of $3.42 billion, a P/E ratio of 37.23, a PEG ratio of 1.51 and a beta of 0.56.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The business had revenue of $346.35 million during the quarter, compared to analyst estimates of $336.83 million. During the same period last year, the company earned $1.24 earnings per share. Haemonetics’s quarterly revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Equities analysts forecast that Haemonetics will post 5.22 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.